Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker... (rs scientists and health plansworldwide....)

Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio

Date:8/23/2007

rs, scientists and health plans worldwide. Visit the company's website at http://www.clda.com for more information.

About Epidauros (http://www.epidauros.com)

Epidauros investigates the genetic factors that influence a person's response to a drug and makes drug development and therapy safer, more efficient and more predictive. The company has established itself as a worldwide leading Pharmacogenetic Research Organization (PRO) providing innovative, integrated and value-added solutions to an international customer base consisting of pharmaceutical companies, CROs and other companies acting in the field of health care.

Thanks to the pharmacogenetic expert knowledge of its qualified scientific team, Epidauros is a competent partner for contract research to reveal new pharmacogenetic targets and polymorphisms that impact drug response. In addition, Epidauros has brought together a network of competent partners to do research and has established its own intellectual property base in the field.

The company is located in Bernried near Munich and was founded as a pioneering company in the field of pharmacogenetics in 1997.

For More Information

Clinical Data

John Schultz

+1-617-527-9933 ext. 3350

jschultz@clda.com

Epidauros

Michael Lutz, Ph.D.

+49 (0)8158 9985 71

michael.lutz@epidauros.com

The Ruth Group

Sara Ephraim (investors)